← Leaderboards
Krishna P Reddy
Massachusetts General Hospital
$8,351,137
Attributed
$8,351,137
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2016–24$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,351,137 · 3
By mechanism
R01$7,422,526 · 2
K01$928,611 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Elyse R Park$12,238,672
- Jonathan P Winickoff$16,869,989
- Margarita Alegria$41,708,508
- Jamie S Ostroff$23,039,922
- Andrea Lynne Ciaranello$11,011,193
Others in their field
Top investigators on “Antiretroviral Therapy”
- James Dennis Neaton · Northwestern University$279,044,427
- Lawrence Corey · Fred Hutchinson Cancer Center$278,220,635
- Constance Ann Benson · University Of California, San Diego$241,336,455
- Carol Nesel · Westat$188,148,170
- Judith S. Currier · University Of California Los Angeles$182,467,520
- Barbara Driver · Westat, Inc.$170,789,549
Research focus
Antiretroviral TherapyAreaInternationalPreventionCost EffectivenessResourcesDesignHiv/TbCause Of DeathReportingSouth AfricaPoliciesCollaborationsAccountingBehavioralPublic HealthCaringEpidemicEconomic OutcomeAdultEconomic ImpactCosts And BenefitsLife ExpectancyClinical Trials
Grant awards (16)
Novel Methods to Inform HIV/TB Clinical Trial Development$809,775
R01 · FY2024 · AI · contact PI
Tobacco Use and Cessation, HIV, and TB in South Africa: Clinical and Economic Outcomes$585,914
R01 · FY2024 · DA · contact PI
Tobacco Use and Cessation, HIV, and TB in South Africa: Clinical and Economic Outcomes (Clinical and public health approaches to tobacco cessation in South Africa supplement)$166,988
R01 · FY2024 · DA · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$803,055
R01 · FY2023 · AI · contact PI
Tobacco Use and Cessation, HIV, and TB in South Africa: Clinical and Economic Outcomes$615,075
R01 · FY2023 · DA · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$810,615
R01 · FY2022 · AI · contact PI
Tobacco Use and Cessation, HIV, and TB in South Africa: Clinical and Economic Outcomes$592,858
R01 · FY2022 · DA · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$804,735
R01 · FY2021 · AI · contact PI
Tobacco Use and Cessation, HIV, and TB in South Africa: Clinical and Economic Outcomes$666,542
R01 · FY2021 · DA · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$838,102
R01 · FY2020 · AI · contact PI
Tobacco Use and Cessation, HIV, and TB in South Africa: Clinical and Economic Outcomes$728,867
R01 · FY2020 · DA · contact PI
Clinical and Economic Outcomes of HIV, Cigarette Smoking, and Smoking Cessation Interventions$186,192
K01 · FY2020 · DA · contact PI
Clinical and Economic Outcomes of HIV, Cigarette Smoking, and Smoking Cessation Interventions$185,670
K01 · FY2019 · DA · contact PI
Clinical and Economic Outcomes of HIV, Cigarette Smoking, and Smoking Cessation Interventions$185,670
K01 · FY2018 · DA · contact PI
Clinical and Economic Outcomes of HIV, Cigarette Smoking, and Smoking Cessation Interventions$185,670
K01 · FY2017 · DA · contact PI
Clinical and Economic Outcomes of HIV, Cigarette Smoking, and Smoking Cessation Interventions$185,409
K01 · FY2016 · DA · contact PI